{
  "id": 12313151,
  "title": "JW Pharmaceutical Reports Empaguard Phase 3 Results",
  "url": "https://urgent.news/2026/10/06/jw-pharmaceutical-reports-empaguard-phase-3-results",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-06T06:06:18.000Z",
  "source": {
    "name": "BusinessKorea",
    "slug": "businesskorea",
    "url": "https://www.businesskorea.co.kr/news/articleView.html?idxno=278292"
  },
  "original_language": "en",
  "account": "JW Pharmaceutical recently presented the Phase 3 clinical trial results for its Type 2 diabetes drug Empaguard at the European Association for the Study of Diabetes meeting (EASD 2026). The study focused on patients whose blood sugar levels remained high despite taking metformin and empagliflozin. Researchers compared a control group receiving the usual single-drug treatment to a treatment group receiving Empaguard, a drug that combines anagliptin. Over 24 weeks at 26 hospitals in South Korea, the Empaguard group saw a 0.81% drop in HbA1c levels, compared to just 0.24% in the control group. This means Empaguard was more effective at lowering blood sugar. More than half (55.7%) of Empaguard patients met the target HbA1c level of 7.0% or lower, compared to only 25.5% of the control group. The trial also found Empaguard improved the function of insulin-producing pancreatic beta cells and significantly lowered fasting blood sugar. Safety data showed the Empaguard group had similar adverse event rates to the control group, with no reports of severe hypoglycemia. Professor Kim Sang-yong, from Chosun University Hospital, highlighted Empaguard's potential to help patients who didn't respond to existing drug combos. JW Pharmaceutical said the positive clinical data confirms the drug's effectiveness and safety, so they will continue offering Empaguard to diabetes patients.",
  "summary": "JW Pharmaceutical recently unveiled the Phase 3 clinical trial results for its Type 2 diabetes combination drug 'Empaguard' at the European Association for the Study of Diabetes annual meeting (EASD 2026).The clinical trial was conducted on patients whose blood glucose levels remained uncontrolled d",
  "key_points": [
    "Empaguard drug combo shows 0.81% HbA1c reduction vs 0.24% control",
    "55.7% of Empaguard patients met 7.0% HbA1c target, 25.5% control",
    "No severe hypoglycemia reported, safety similar to control group"
  ],
  "editors_take": "The successful Phase 3 trial results for Empaguard suggest it could become a treatment option for Type 2 diabetes patients who do not respond well to existing medication combinations.",
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}